Xilio Therapeutics (XLO) Receivables - Net (2024)
Xilio Therapeutics (XLO) reported Receivables - Net of $30.0 million for Q1 2024.
Xilio Therapeutics (XLO) Receivables - Net (2024) Analysis & Trends
Xilio Therapeutics (XLO) has 1 years of Receivables - Net data on file, last reported at $30.0 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,222.41 Bn | 67,222.13 Bn | - |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 472.06 Bn | 467.27 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.10 Bn | 114.85 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.25 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.50 Bn | 959.66 Mn |
| 10 | Xilio Therapeutics | 144.68 Mn | -5.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 30.00 Mn |
| Mar 31, 2024 | 30.00 Mn |